1Lamm DL. Prophylaxis for recurrent transitional cell carcinoma. Urology,1991,37(suppl 5):21.
2Nakagawa S, Kojima M, Nakao M, et al. Fluorescence,microscopic study on absorption of adriamycin through the rat bladder epithelium. Tohoku J Exp Med,1987,153: 227.
3Matamura Y, Tsushima T O zaki Y , et al ,Intravesical chemotherapy with 4'-epi-adriamycin in patients with superficial bladder tumours. Cancer Chemother Pharmacol, 1986,16.
4Calais da Silva F.Denis L,Bono A.et al. Intravesical chemoresection with 4`-epidoxorubicin in patients with superficial bladder tumours. Eur Urol, 1988,4 : 207.
5Cumming, JA, Kirk D, Newling DW, et al. A multicentre phase I study of intravesical epirubicin in the treatment of superficial bladder turnout. Eur Urol,1990,17:20.
6Popert RJM, Goodall J, Coptcoat M J, et al Superficial bladder cancer:the response of a marker tumour to a single intravesical instillation of epirubicin. Br d Uro1,1994,195.
7Skarlos DV, Aravantinos G, Linardou E, et al Chemotherapy with methotrexate,vinblastine,epirubicin and carboplatin (Carbo-MVE) in transitional cell urotheliat canter. A Hellenic Co-Operative Oncology Group Study. Eur Urol, 1997,31 : 470.
8Pronzato P, Bertelli G, Bruna F, et al Intensified M-VEC chemotherapy with Co-CSF support as outpatient for advanced bladder cancer. Anticancer Res. 1997,17 : 2325.
9Ali-el-Dein B, EI-Baz M, Aly An, et al. Intravesical epirubicin versus doxorubicin for superficial bladder tumors(stages pTaand pT1) :a randomized prospective study.J Urol, 1997,158:68.
10Abel PD, Hall RR, Williams G. Should pT1 transitional cell cancer of the bladder still be classified as superficial?Br J Urol,1988,62:235.
